The purpose of this study is to evaluate the efficacy and safety of tebentafusp-based regimens, including tebentafusp monotherapy and in combination with anti-PD1 vs investigator choice (including clinical trials of investigational agents, salvage therapy per local standard of care \[SoC\], best supportive care \[BSC\] on protocol survivor follow up) in patients with advanced non-ocular melanoma.
Protocol Amendment History
9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2022-09-19; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Recruiting2023-02-21